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ABSTRACT
Objective To study the inter-observer variation related to
extraction of continuous and numerical rating scale data
from trial reports for use in meta-analyses.
Design Observer agreement study.
Data sources A random sample of 10 Cochrane reviews
that presented a result as a standardisedmean difference
(SMD), the protocols for the reviews and the trial reports
(n=45) were retrieved.
Data extraction Five experiencedmethodologists and five
PhD students independently extracted data from the trial
reports for calculation of the first SMD result in each
review. The observers did not have access to the reviews
but to the protocols, where the relevant outcome was
highlighted. The agreementwas analysed at both trial and
meta-analysis level, pairing the observers in all possible
ways (45 pairs, yielding 2025 pairs of trials and 450 pairs
of meta-analyses). Agreement was defined as SMDs that
differed less than 0.1 in their point estimates or
confidence intervals.
Results The agreement was 53% at trial level and 31% at
meta-analysis level. Including all pairs, the median
disagreement was SMD=0.22 (interquartile range 0.07-
0.61). The experts agreed somewhat more than the PhD
studentsat trial level (61% v46%),but not atmeta-analysis
level. Important reasons for disagreement were differences
in selection of time points, scales, control groups, and type
of calculations; whether to include a trial in the meta-
analysis; and data extraction errorsmade by the observers.
In 14 out of the 100 SMDs calculated at the meta-analysis
level, individual observers reached different conclusions
than the originally published review.
Conclusions Disagreements were common and often
larger than the effect of commonly used treatments.Meta-
analyses using SMDs are prone to observer variation and
should be interpretedwith caution. The reliability ofmeta-
analyses might be improved by having more detailed
review protocols, more than one observer, and statistical
expertise.
INTRODUCTION
Systematic reviews of clinical trials, withmeta-analyses
if possible, are regarded as the most reliable resource
for decisions about prevention and treatment. They
should be based on a detailed protocol that aims to
reduce bias by pre-specifying methods and selection
of studies and data.1 However, as meta-analyses are
usually based on data that have already been pro-
cessed, interpreted, and summarised by other
researchers, data extraction can be complicated and
can lead to important errors.2
There is often a multiplicity of data in trial reports
that makes it difficult to decide which ones to use in a
meta-analysis. Furthermore, data are often incomple-
tely reported,2 3 which makes it necessary to perform
calculations or impute missing data, such as missing
standard deviations. Different observers may get dif-
ferent results, but previous studies on observer varia-
tion have not been informative, because of few
observers, few trials, or few data.4 5 We report here a
detailed study of observer variation that explores the
sources of disagreement when extracting data for cal-
culation of standardised mean differences.
METHODS
Using a computer generated list of random numbers,
we selected a random sample of 10 recent Cochrane
reviews published in the Cochrane Library in issues 3
or 4 in 2006 or in issues 1 or 2 in 2007. We also
retrieved the reports of the randomised trials that
were included in the reviews and the protocols for
each of the reviews. Only Cochrane reviews were eli-
gible, as they are required to have a pre-specified pub-
lished protocol.
We included reviews that reported at least one result
as a standardisedmean difference (SMD). The SMD is
used when trial authors have used different scales for
measuring the same underlying outcome—for exam-
ple, pain can be measured on a visual analogue scale
or on a 10-point numeric rating scale. In such cases, it is
necessary to standardise the measurements on a uni-
form scale before they can be pooled in a meta-analy-
sis. This is typically achieved by calculating the SMD
for each trial, which is the difference inmeans between
the two groups, divided by the pooled standard devia-
tion of the measurements.1 By this transformation, the
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outcome becomes dimensionless and the scales
become comparable, as the results are expressed in
standard deviation units.
The first SMD result in each review that was not
based on a subgroup result was selected as our index
result. The index result had to be based on two to 10
trials and on published data only (that is, there was no
indication that the review authors had received addi-
tional outcome data from the trial authors).
Five methodologists with substantial experience in
meta-analysis and five PhD students independently
extracted the necessary data from the trial reports for
calculation of the SMDs. The observers had access to
the review protocols but not to the completed
Cochrane reviews and the SMD results. An additional
researcher (BT) highlighted the relevant outcome in
the protocols, along with other important issues such
as pre-specified time points of interest, which inter-
vention was the experimental one, and which was the
control. If information was missing regarding any of
these issues, the observers decided by themselves
what to select from the trial reports. The observers
received the review protocols, trial reports, and a
copy of the Cochrane Handbook for Systematic Reviews6
as PDF files.
The data extraction was performed during one week
when the 10 observers worked independently at the
same location in separate rooms. The observers were
not allowed to discuss the data extraction. If the data
were available, the observers extracted means, stan-
dard deviations, and number of patients for each
group; otherwise, they could calculate or impute the
missing data, such as from an exact P value. The obser-
vers also interpreted the sign of the SMD results—that
is, whether a negative or a positive result indicated
superiority of the experimental intervention. If the
observers were uncertain, the additional researcher
retrieved the paper that originally described the scale,
and the direction of the scale was based on this infor-
mation. All calculations were documented, and the
observers provided information about any choices
they made regarding multiple outcomes, time points,
and data sources in the trial reports.During theweek of
data extraction the issue of whether the observers
could exclude trials emerged, as there were instances
where the observers were unable to locate any relevant
data in the trial reports or felt that the trial did notmeet
the inclusion criteria in the Cochrane protocol. It was
decided that observers could exclude trials, and the
reasons for exclusion were documented.
Based on the extracted data, the additional
researcher calculated trial and meta-analysis SMDs
for each observer using Comprehensive Meta-Analy-
sis Version 2. To allow comparison with the originally
published meta-analyses, the same method (random
effects or fixed effect model) was used as that in the
published meta-analysis. In cases where the observers
had extracted two sets of data from the same trial—for
example, because there were two control groups—the
datawere combined so that only a single SMD resulted
from each trial.1
Agreement between pairs of observers was assessed
at both meta-analysis and trial level, pairing the 10
observers in all possible ways (45 pairs). This provides
an indication of the likely agreement that might be
expected in practice, since two independent observers
are recommended when extracting data from papers
for a systematic review.12 5 6 Agreement was defined
as SMDs that differed less than 0.1 in their point esti-
mates and in their confidence intervals. The cut point
of 0.1 was chosen becausemany commonly used treat-
ments have an effect of 0.1 to 0.5 compared with
placebo2; furthermore, an error of 0.1 canbe important
when two active treatments have been compared, for
there is usually little difference between active treat-
ments. Confidence intervals were not calculated, as
the data from the pairings were not independent.
To determine the variation in meta-analysis results
that couldbeobtained from themultiplicity of different
SMD estimates across observers, we conducted a
Monte Carlo simulation for each meta-analysis. In
each iteration of the simulation, we randomly sampled
one observer for each trial and entered his or her SMD
(and standard error) for that trial into a meta-analysis.
Thus each sampledmeta-analysis contained SMD esti-
mates from different observers. If the sampled obser-
ver excluded the trial fromhis or hermeta-analysis, the
simulated meta-analysis also excluded that trial. We
examined the distribution of meta-analytic SMD esti-
mates across 10 000 simulations.
RESULTS
The flowchart for inclusion of meta-analyses is shown
in figure 1.Out of 32potentially eligiblemeta-analyses,
the final sample consisted of 10.7-16 The 10 meta-ana-
lyses comprised 45 trials, which yielded 450 pairs of
observers at the meta-analysis level and 2025 pairs at
the trial level.
The level of information in the review protocols is
given in table 1. None of the review protocols con-
tained information on which scales should be pre-
ferred. Three protocols gave information about
which time point to select and fourmentionedwhether
change from baseline or values after treatment should
be preferred. Nine described which type of control
group to select, but none reported any hierarchy
Potentially eligible meta-analyses (n=32)
Eligible meta-analyses (n=20)
Random sample of eligible meta-analyses (n=10)
SMD = standardised mean difference
Excluded (n=12):
  Not based exclusively on randomised trials (n=6)   
  No pooled SMD (n=2)
  SMD results based on unpublished data (n=2)
  Only subgroup result (n=1)
  No available protocol (n=1)
Fig 1 | Flowchart for selection of meta-analyses
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among similar control groups or any intentions to com-
bine such groups.
Theoutcomes analysed in the 10meta-analyseswere
diverse: in six, the outcome was a clinician reported
score (three symptom scores, one general functioning
score, one hepatic density score, and one neonatal
score); in one, it was objective (range of movement in
ankle joints); and in three, it was self reported (pain,
tinnitus, and patient knowledge).
Agreement at trial level
In table 2 the different levels of agreement are shown.
Across trials, the agreementwas 53% for the 2025 pairs
(61% for the 450 pairs of methodologists, 46% for the
450 pairs of PhD students, and 52% for the 1125mixed
pairs). The agreement rates for the individual trials ran-
ged from 4% to 100%. Agreement between all obser-
vers was found for four of the 45 trials.
Table 3 presents the reasons for disagreement,
which fell into three broad categories: different
choices, exclusion of a trial, and data extraction errors.
The different choices mainly concerned cases with
multiple groups to choose from when selecting the
experimental or the control groups (15 trials), which
time point to select (nine trials), which scale to use
(six trials), and different ways of calculating or imput-
ing missing numbers (six trials). The most common
reasons for deciding to exclude a trial was that the
trial did not meet the inclusion criteria described in
the protocol for the review (14 trials) and that the
reporting was so unclear that data extraction was not
possible (14 trials). Data extraction errors were less
common but involved misinterpretation of the direc-
tion of the effect in four trials.
The importance of which standard deviation to use
was underpinned in a trial that did not report standard
deviations.17 The only reported data on variability
were F test values and P values from a repeated mea-
sure, analysis of variance, performed on changes from
baseline. The five PhD students excluded the trial
because of the missing data, whereas the five experi-
enced methodologists imputed five different standard
deviations. One used a standard deviation from the
report originally describing the scale, another used
the average standard deviation reported in the other
trials in the meta-analysis, and the other three obser-
vers calculated standard deviations based on the
reported data, using three different methods. In addi-
tion, one observer selected a different time point from
Table 1 | Level of information provided in the 10 meta-analysis protocols used in this study for data extraction
Information
Meta-analysis
Gava
et al7
Woodford
et al8
Martinez
et al9
Orlando
et al10
Buckley
et al11
Ipser
et al12
Mistiaen
et al13
Afolabi
et al14
Uman
et al15
Moore
et al16
Possible control group(s) √ √ √ √ √ √ √ √ √
Hierarchy of control groups √* √*
Which time point to select √ √ √
Whether to use change from baseline or values after treatment √ √ √ √
Hierarchy of measuring methods or scales
*Only one possible control group stated
Table 2 | Levels of overall agreement between observer pairs in the calculated standardised
mean differences (SMDs)* from 10 meta-analyses (which comprised a total of 45 trials)
Observer pairs No (%) of pairs in agreement
Trial level
All pairs (n=2025): 1068 (53)
Methodologists (n=450) 273 (61)
PhD students (n=450) 209 (46)
Mixed pairs (n=1125) 586 (52)
Meta-analysis level
All pairs (n=450): 138 (31)
Methodologists (n=100) 33 (33)
PhD students (n=100) 27 (27)
Mixed pairs (n=250) 78 (31)
*Agreement defined as SMDs that differed less than 0.1 in their point estimates and in their 95% confidence
intervals.
Table 3 | Reasons for disagreement among the 41 trials on
which the observer pairs disagreed in the calculated
standardised mean differences
Reason for disagreement No of trials*
Different choices regarding:
Groups, pooling, splitting 15
Timing 9
Scales 6
Different calculations or imputations 6
Dropouts 4
Use of change from baseline or values
after treatment
4
Individual patient data 1
Exclusion of trials because:
Did not meet protocol inclusion criteria 14
Reporting unclear 14
Missing data 7
Could not or would not calculate 2
Only change from baseline or only
values after treatment
2
Errors due to:
Misreading or typing error 4
Direction of effect 4
Standard error taken as standard
deviation
2
Rounding 1
Calculation error 1
*There may be more than one reason for disagreement per trial.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 7
the others. The different standard deviations resulted
in different trial SMDs ranging from −1.82 to 0.34 in
their point estimates.
Agreement at meta-analysis level
Across the meta-analyses, the agreement was 31% for
the 450 pairs (33% for the 100 pairs of methodologists,
27% for the 100 pairs of PhD students, and 31% for the
250mixed pairs) (table 2). The agreement rates for the
individual meta-analyses ranged from 11% to 80%
(table 4). Agreement between all observers was not
found for any of the 10 meta-analyses.
The distribution of the disagreements is shown in
figure 2. Ten per cent agreed completely, 21% had a
disagreement below our cut point of 0.1, 38% had a
disagreement between 0.1 and 0.49, and 28% dis-
agreed by at least 0.50 (including 10% that had dis-
agreements of ≥1). The last 18 pairs (4%) were not
quantifiable since one observer excluded all the trials
from two meta-analyses. The median disagreement
was SMD=0.22 for the 432 quantifiable pairs with an
interquartile range from 0.07 to 0.61. There were no
differences between the methodologists and the PhD
students (table 2).
Figure 3 shows the SMDs calculated by each of the
10 observers for the 10 meta-analyses, and the results
from the originally published meta-analyses. Out of
the total of 100 calculated SMDs, seven values corre-
sponding to significant results in the originally pub-
lished meta-analyses were now non-significant, three
values corresponding to non-significant results were
now significant, and four values, which were related
to the same published meta-analysis, showed a signifi-
cantly beneficial effect for the control group whereas
the original publication reported a significantly bene-
ficial effect for the experimental group.11 The SMDs
for this meta-analysis had particularly large disagree-
ments, partly because only two trials were included,
leaving less possibility for the pooled result to average
out. The reasons for the large disagreements were
diverse and included selection of different time points,
control groups, intervention groups, measurement
scales, and whether to exclude one of the trials.
The results of theMonte Carlo investigation are pre-
sented in figure 4. For four of the 10 meta-
analyses7 11 13 14 there was considerable variation in
the potential SMDs, allowing for differences in SMDs
of up to 3. In two of these, around half of the distribu-
tion extended beyond even the confidence interval for
the published result of the meta-analysis. 7 11 The other
meta-analyses had three and two trials respectively,
and the distributions reflect the wide scatter of SMDs
from these trials.
DISCUSSION
We found that disagreements between observers were
common and often large. Ten per cent of the disagree-
ments at the meta-analysis level amounted to an SMD
of at least 1, which is far greater than the effect of most
of the treatments we use compared with no treatment.
As an example, the effect of inhaled corticosteroids on
asthma symptoms, which is generally regarded as sub-
stantial, is 0.49.18 Important reasons for disagreement
were differences in selection of time points, scales, con-
trol groups, and type of calculations, whether to
include a trial in the meta-analysis, and finally data
extraction errors made by the observers.
The disagreement depended on the reporting of data
in the trial reports and on how much room was left for
decision in the review protocols. One of the reviews
exemplified the variation arising from a high degree
of multiplicity in the trial reports combined with a
review protocol leaving much room for choice.11 In
the review protocol, the time point was described as
“long term (more than 26 weeks),” but in the two trials
included in the meta-analysis there were several
options. For one trial,19 there were two: end of treat-
ment (which lasted 9 months) or three month follow-
up. For the other,20-22 there were three: 6, 12, and
18 month follow-up (treatment lasted 3 weeks). The
observers used all the different time points, and all
had a plausible reason for their choice: in concordance
Table 4 | Levels of agreement at the meta-analysis level between observer pairs in the
calculated standardised mean differences (SMDs) from 10 meta-analyses*
Meta-analysis
No (%) of pairs in agreement
All pairs
(n=45) Methodologist (n=10) Students (n=10)
Mixed pairs
(n=25)
Gava et al7 6 (13) 1 (10) 0 (0) 5 (20)
Woodford et al8 11 (24) 2 (20) 1 (10) 8 (32)
Martinez et al9 7 (16) 3 (30) 1 (10) 3 (12)
Orlando et al10 5 (11) 1 (10) 2 (20) 2 (8)
Buckley et al11 6 (13) 1 (10) 1 (10) 4 (16)
Ipser et al12 13 (29) 4 (40) 2 (20) 7 (28)
Mistiaen et al13 16 (36) 6 (60) 2 (20) 8 (32)
Afolabi et al14 28 (62) 6 (60) 6 (60) 16 (64)
Uman et al15 36 (80) 6 (60) 10 (100) 20 (80)
Moore et al16 10 (22) 3 (30) 2 (20) 5 (20)
*Agreement defined as SMDs that differed less than 0.1 in their point estimates and in their 95% confidence
intervals.
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Fig 2 | Sizes of the disagreements between observer pairs in the calculated standardised mean
differences (SMDs) from 10 meta-analyses. Comparisons are at the meta-analysis level. (*All
the underlying trials were excluded)
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with the time point used in the other trial, the maxi-
mum period of observation, and the least drop out of
patients.
Strengths and weaknesses
The primary strength of our study is that we took a
broad approach and showed that there are other
important sources of variation in meta-analysis results
than simple errors. Furthermore, we included a consid-
erable number of experienced aswell as inexperienced
observers and a large number of trials to elucidate the
sources of variation and their magnitude. Finally, the
study setup ensured independent observations accord-
ing to the blueprint laid out in the review protocols and
likely mirrored the independent data extraction that
ideally should happen in practice.
The experimental setting also had limitations. Single
data extraction producesmore errors than double data
extraction.5 In real life, some of the errors we made
would therefore probably have been detected before
the data were used for meta-analyses, as it is recom-
mended for Cochrane reviews that there should be at
least two independent observers and that any disagree-
ment should be resolved by discussion and, if neces-
sary, arbitration by a third person.1 We did not
perform a consensus step, as the purpose of our study
was to explore howmuch variation would occur when
data extraction was performed by different observers.
However, given the amount of multiplicity in the trial
reports and the uncertainties in the protocols, it is likely
that even pairs of observers would disagree consider-
ably with other pairs.
Other limitationswere that the observerswere under
time pressure, although only one person needed more
time, as he fell ill during the assigned week. The obser-
vers were presented with protocols they had not devel-
oped themselves, based on research questions theyhad
not asked, and in disease areas where they weremostly
not experts. Another limitation is that, even though
one of the exclusion criteria was that the authors of
the Cochrane review had not obtained unpublished
data from the trial authors, it became apparent during
data extraction that some of the trial reports did not
contain the data needed for the calculation of an
SMD. It would therefore have been helpful to contact
trial authors.
Other similar research
The SMD is intended to give clinicians and policy-
makers the most reliable summary of the available
-2 2-1 0 1
Gava et al7 Martinez et al9 Woodford et al8 Orlando et al10 Buckley et al11
-2 2-1 0 1 -2 2-1 0 1 -2 2-1 0 1 -2 2-1 0 1
-2 2-1 0 1
Ipser et al12 Uman et al15 Moore et al16 Mistiaen et al13 Afolabi et al14
SMDSMDSMDSMDSMD
-2 2-1 0 1 -2 2-1 0 1 -4 5-1-3-5 -2 20 1 43 -4 5-1-3-5 -2 20 1 43
Experienced methodologists PhD students Result from published meta-analysis
Fig 3 | Forest plots of standardised mean differences (SMDs) and 95% confidence intervals calculated from data from each of the 10 observers for the 10 meta-
analyses
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trial evidence when the outcomes have beenmeasured
on different continuous or numeric rating scales. Sur-
prisingly, the method has not previously been exam-
ined in any detail for its own reliability. Previous
research has been sparse and has focused on errors in
data extraction.2 4 5 In one study, the authors found
errors in 20 of 34 Cochrane reviews, but, as they gave
no numerical data, it is not possible to judge how often
these were important.4 In a previous study of 27 meta-
analyses, of which 16 were Cochrane reviews,2 we
could not replicate the SMD result for at least one of
the two trials we selected for checking from eachmeta-
analysis within our cut point of 0.1 in 10 of the meta-
analyses.Whenwe tried to replicate these 10meta-ana-
lyses, including all the trials, we found that seven of
themwere erroneous; one was subsequently retracted,
and in two a significant difference disappeared or
appeared.2 The present study adds to the previous
research by also highlighting the importance of differ-
ent choiceswhen selecting outcomes formeta-analysis.
The results of our study apply more broadly than to
meta-analyses using the SMD, as many of the reasons
for disagreement were not related to the SMDmethod
but would be important alsowhen analysing data using
the weighted mean difference method, which is the
method of choice when the outcome data have been
measured on the same scale.
Conclusions
Disagreementswere commonandoften larger than the
effect of commonly used treatments. Meta-analyses
using SMDs are prone to observer variation and
should be interpreted with caution. The reliability of
meta-analyses might be improved by having more
detailed review protocols, more than one observer,
and statistical expertise.
Review protocols should be more detailed and made
permanently available, also after the review is published,
to allow other researchers to check that the review was
done according to the protocol. In February 2008, the
Cochrane Collaboration updated its guidelines and
recommended that researchers in theirprotocols list pos-
sible ways of measuring the outcomes—such as using
different scales or time points—and specify which ones
to use. Our study provides strong support for such pre-
cautions. Reports of meta-analyses should also follow
published guidelines123 to allow for sufficient critical
appraisal. Finally the reporting of trials needs to be
improved, according to the recommendations in the
CONSORT statement,24 reducing the need for calcula-
tions and imputation of missing data.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Incorrect data extraction in meta-analyses can lead to false results
Multiplicity in trial reports invites variation in data extraction, as different judgments will lead
to different choices about which data to extract
The impact of these different errors and choices on meta-analysis results is not clear
WHAT THIS STUDY ADDS
There is considerable observer variation in data extraction and decisions on which trials to
include
The reasons for disagreement are different choices and errors
The impact on meta-analyses is potentially large
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